Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study

被引：2
|
作者：
Lee, C. [1 ]
Tang, Y. [1 ]
Schroeder, C. [1 ]
Zhang, J. [1 ]
Nguyen-Cleary, T. [1 ]
Mullin, S. [1 ]
Ma, M. [1 ]
Lyon, N. [1 ]
Grundy, J. [1 ]
机构：
[1] Arena Pharmaceut Inc, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.415
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P291
引用
收藏
页码：S321 / S322
页数：4
相关论文
共 50 条
  • [1] Pharmacokinetics (PK), Safety, and Tolerability of Etrasimod (APD334) in Participants With Mild, Moderate, or Severe Hepatic Impairment: A Single-Dose, Open-Label, Parallel-Group Study
    Lee, Caroline
    Tang, Yong
    Schroeder, Cassandra
    Zhang, Jinkun
    Nguyen-Cleary, Thai
    Ma, Michael
    Lyon, Naomi
    Grundy, John S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S327 - S328
  • [2] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Bola Tayo
    Lesley Taylor
    Farhad Sahebkar
    Gilmour Morrison
    Clinical Pharmacokinetics, 2020, 59 : 747 - 755
  • [3] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Tayo, Bola
    Taylor, Lesley
    Sahebkar, Farhad
    Morrison, Gilmour
    CLINICAL PHARMACOKINETICS, 2020, 59 (06) : 747 - 755
  • [4] A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
    Taylor, Lesley
    Crockett, Julie
    Tayo, Bola
    Morrison, Gilmour
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08): : 1110 - 1119
  • [5] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
    Gardin, Anne
    Dodman, Angela
    Kalluri, Sampath
    Neelakantham, Srikanth
    Tan, Xuemei
    Legangneux, Eric
    Shakeri-Nejad, Kasra
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 54 - 65
  • [6] Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study
    David, Olivier J.
    Pryce, Maxwell
    Meiser, Karin
    Picard, Franck
    Emotte, Corinne
    Kobalava, Zhanna
    Moiseev, Valentin
    Schmouder, Robert
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (10) : 847 - 854
  • [7] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
    Shakeri-Nejad, Kasra
    Aslanis, Vassilios
    Veldandi, Uday Kiran
    Gardin, Anne
    Zaehringer, Andreas
    Dodman, Angela
    Su, Zhenzhong
    Legangneux, Eric
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 41 - 53
  • [8] Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
    Kasichayanula, Sreeneeranj
    Liu, Xiaoni
    Zhang, Weijiang
    Pfister, Marc
    LaCreta, Frank P.
    Boulton, David W.
    CLINICAL THERAPEUTICS, 2011, 33 (11) : 1798 - 1808
  • [9] Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study
    Chattopadhyay, Niladri
    Riecke, Kai
    Ligges, Sandra
    Zimmermann, Torsten
    Halabi, Atef
    Schultze-Mosgau, Marcus-Hillert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 2011 - 2021
  • [10] Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
    Peveling-Oberhag, Jan
    Zeuzem, Stefan
    Yong, Wei Peng
    Kunz, Tiffany
    Paquet, Thierry
    Bouillaud, Emmanuel
    Urva, Shweta
    Anak, Oezlem
    Sellami, Dalila
    Kobalava, Zhanna
    CLINICAL THERAPEUTICS, 2013, 35 (03) : 215 - 225
12345